Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture
Authors' conclusion
Postfracture mortality is higher in people who discontinue risedronate, but not alendronate, for 1 or 2 years after being adherent to treatment for at least 5 years. The type of bisphosphonate may be a factor to consider when planning drug holidays.
Study context
- Population
- Patients with hip fracture in Victoria, Australia, 2014–2018, adherent (medication possession ratio ≥80%) to oral alendronate or risedronate for ≥5 years before fracture
- Participants
- 365 patients
- Exposure
- Discontinuation (drug holiday) of oral bisphosphonate for 1 or 2 years vs continued use before hip fracture
- Outcome
- Postfracture mortality
Methodological detailspopulation-based, group-based trajectory modeling
- Population-based
- Group-based trajectory modeling
Main finding
As reported in the abstract
Each group vs continuedHazard ratio (95% CI)
Discontinued 1 yearalendronate
0.59(0.29–1.18)
Discontinued 2 yearsalendronate
1.05(0.57–1.93)
HR
- Discontinued 1 year · risedronate
- 2.37 (95% CI 1.24–4.53)
- Discontinued 2 years · risedronate
- 3.08 (95% CI 1.48–6.41)
Observational data: associations, not effects.
Original publication
Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture. J Clin Endocrinol Metab. Published 17 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →